Publicação
Botulinum toxin type A for the prevention of migraines : an umbrella review of systematic reviews
| datacite.subject.fos | Ciências Médicas::Ciências da Saúde | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Chamani, Goli | |
| dc.contributor.author | Jasim, Hajer | |
| dc.contributor.author | Minston, Ava | |
| dc.contributor.author | Dias, Marlon Ferreira | |
| dc.contributor.author | Poluha, Rodrigo Lorenzi | |
| dc.contributor.author | Gonçalves, Daniela A. Godoi | |
| dc.contributor.author | Christidis, Maria | |
| dc.contributor.author | Al-Moraissi, Essam Ahmed | |
| dc.contributor.author | Christidis, Nikolaos | |
| dc.contributor.author | Canales, Giancarlo De la Torre | |
| dc.contributor.author | Ernberg, Malin | |
| dc.date.accessioned | 2026-06-02T13:27:37Z | |
| dc.date.available | 2026-06-02T13:27:37Z | |
| dc.date.issued | 2026-01 | |
| dc.description.abstract | Botulinum toxin type A (BoNT-A) is an established preventive therapy for chronic migraines; however, uncertainty remains regarding its comparative efficacy and safety. Thus, we aimed to summarize current evidence from high-quality systematic reviews of the therapeutic effects of BoNT-A in migraine management. An umbrella review was conducted following PRISMA guidelines and registered in PROSPERO. High-quality systematic reviews with meta-analysis evaluating BoNT-A efficacy were identified through five databases up to August 2024. Primary outcomes included monthly headache frequency and severity. Methodological quality and risk of bias were assessed using the umbrella review checklist. Fourteen articles were included. Overall, quantitative evidence indicated favorable effects of BoNT-A compared with placebo for chronic migraines, across headache frequency, headache severity, and acute medication use, but less efficacy than topiramate and the CGRP monoclonal antibodies (CGRPmAbs) galcanezumab and fremanezumab. Though the adverse events were frequent, BoNT-A was generally well-tolerated. Comparative data suggested superior tolerability versus topiramate and a safety profile like CGRPmAbs. Although botulinum toxin type A is widely used as a preventive treatment for chronic migraines, the available evidence supports its efficacy at a moderate level. Further head-to-head and long-term analyses are needed to clarify its comparative role alongside newer biologic treatments. | eng |
| dc.identifier.citation | Chamani G, Jasim H, Minston A, Dias MF, Poluha RL, Gonçalves DAG, Christidis M, Al-Moraissi EA, Christidis N, De la Torre Canales G, et al. Botulinum Toxin Type A for the Prevention of Migraines: An Umbrella Review of Systematic Reviews. Toxins. 2026; 18(1):33. https://doi.org/10.3390/toxins18010033 | |
| dc.identifier.doi | 10.3390/toxins18010033 | |
| dc.identifier.issn | 2072-6651 | |
| dc.identifier.uri | http://hdl.handle.net/10400.26/63501 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | MDPI | |
| dc.relation.hasversion | https://doi.org/10.3390/toxins18010033 | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | botulinum toxin type A | |
| dc.subject | chronic migraine | |
| dc.subject | umbrella review | |
| dc.subject | quality of life | |
| dc.subject | CGRP monoclonal antibodies | |
| dc.subject | preventive therapy | |
| dc.title | Botulinum toxin type A for the prevention of migraines : an umbrella review of systematic reviews | eng |
| dc.type | contribution to journal | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 1 | |
| oaire.citation.startPage | 33 | |
| oaire.citation.title | Toxins | |
| oaire.citation.volume | 18 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |